LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancerBusiness Wire • 03/16/22
Merck to stop clinical trial testing Keytruda with AstraZeneca's Lynparza in prostate cancer patientsMarket Watch • 03/15/22
SVB Leerink: AstraZeneca's Lynparza could bring in $9.7 billion in sales by 2028Market Watch • 03/14/22
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business UpdatesPRNewsWire • 03/04/22